Erlotinib as maintenance therapy in patients with advanced non-small cell lung cancer: a pooled analysis of three randomized trials
F Petrelli, K Borgonovo, M Cabiddu, S Barni - Anti-cancer drugs, 2011 - journals.lww.com
Three randomized trials (SATURN, ATLAS and IFCT-GFPC 0502) have demonstrated that
the oral antiepidermal growth factor receptor tyrosine kinase inhibitor erlotinib can improve
progression-free survival (PFS) and overall survival (OS), as maintenance therapy after first-
line chemotherapy in advanced non-small cell lung cancer. We pooled the results of these
three trials by performing a meta-analysis of hazard ratios (HRs) and the 95% confidence
intervals (CIs) for the PFS and the OS for maintenance erlotinib versus observation, standard …
the oral antiepidermal growth factor receptor tyrosine kinase inhibitor erlotinib can improve
progression-free survival (PFS) and overall survival (OS), as maintenance therapy after first-
line chemotherapy in advanced non-small cell lung cancer. We pooled the results of these
three trials by performing a meta-analysis of hazard ratios (HRs) and the 95% confidence
intervals (CIs) for the PFS and the OS for maintenance erlotinib versus observation, standard …
以上显示的是最相近的搜索结果。 查看全部搜索结果